Analysis of Fingolimod Hydrochloride According to the USP Monograph 1745

Importance of the Topic

The United States Pharmacopeia (USP) provides essential guidelines and reference standards for the quality control of pharmaceutical substances. HPLC methods compliant with USP monographs ensure drug identity, purity, strength and potency, critical for regulatory approval and patient safety. Fingolimod Hydrochloride, a key immunosuppressant for multiple sclerosis, requires reliable analysis in quality assurance environments.

Objectives and Study Overview

This study demonstrates the gradient HPLC analysis of Fingolimod Hydrochloride according to USP Monograph 1745. It evaluates system suitability, method precision, and peak performance using Shimadzu’s Prominence-i LC-2030C Plus system and Shim-pack GISS C18 column.

Methodology and Instrumentation

The analysis was carried out under gradient conditions with:

• Mobile phase A: 0.1% phosphoric acid in water
• Mobile phase B: acetonitrile
• Gradient program: 0–20 min (80% A to 5% A), 20–23 min (5% A), re-equilibration to 80% A by 23.1 min, hold to 33 min
• Diluent: 1:1 mixture of solutions A and B
• Fingolimod Hydrochloride standard: 0.6 mg/mL
• Column temperature: 40°C
• Flow rate: 0.8 mL/min, injection volume: 5 µL
• Detection: UV at 215 nm

Used Instrumentation

• Shimadzu Prominence-i LC-2030C Plus HPLC system (degasser, quaternary pump, autosampler with cooler, column oven, UV-Vis detector)
• Shim-pack GISS C18 analytical column, 3 µm, 3.0 × 150 mm

Main Results and Discussion

The retention time of Fingolimod Hydrochloride was approximately 10.5 minutes. System suitability met USP criteria: relative standard deviation for retention time (0.03%) and peak area (0.16%) well below the maximum of 0.73%, and tailing factor of 3.6 below the limit of 5. These results confirm method precision, peak symmetry, and reproducibility.

Benefits and Practical Applications

• Robust compliance with USP monograph requirements
• High reproducibility for quality control laboratories
• Rapid column equilibration and stable baseline facilitating routine analysis
• Suitable for pharmaceutical R&D and manufacturing QA/QC

Future Trends and Applications

Advances in column materials and UHPLC technology will further reduce run times and solvent consumption. Integration of automated method development and AI-driven data analysis can enhance throughput and predictive maintenance. Portable and miniaturized HPLC systems promise on-site pharmaceutical testing capabilities.

Conclusion

The combination of the Prominence-i LC-2030C Plus system and Shim-pack GISS C18 column provides a reliable and USP-compliant method for analyzing Fingolimod Hydrochloride. The validated parameters demonstrate excellent precision and peak performance, making this approach well-suited for routine drug quality control.

References

1. Fingolimod Hydrochloride. NCBI MeSH ID 2009891
2. USP Monograph, Fingolimod Hydrochloride, USP 40–NF35, Second Supplement